BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7373744)

  • 41. Optimal pricing of hospital services.
    Dittman DA; Morey RC
    Inquiry; 1981; 18(4):311-21. PubMed ID: 6460697
    [No Abstract]   [Full Text] [Related]  

  • 42. Surviving prospective reimbursement: how computers can help contain lab costs.
    Aller RD
    Pathologist; 1985 Apr; 39(4):12-6. PubMed ID: 10317589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hospital-based physicians: current issues and descriptive evidence.
    Steinwald B
    Health Care Financ Rev; 1980; 2(1):63-75. PubMed ID: 10309258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generating revenue through laboratory testing.
    Hannon F
    Hosp Entrep Newsl; 1987 Jun; 3(1):1-2, 8. PubMed ID: 10325197
    [No Abstract]   [Full Text] [Related]  

  • 45. TEFRA: a primer for the uninitiated.
    Kenety WH
    Pathologist; 1983 Sep; 37(9):655-8. PubMed ID: 10299327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fulfilling Medicare's criteria for consultative services.
    Pastuszak WT
    Pathologist; 1985 Jun; 39(6):31-4. PubMed ID: 10300151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Directing the post-TEFRA laboratory.
    Sharp JW
    Pathologist; 1985 Feb; 39(2):15-8. PubMed ID: 10270443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What the new Medicare rules mean to pathologists.
    Cole GW
    MLO Med Lab Obs; 1983 May; 15(5):50-4. PubMed ID: 10299168
    [No Abstract]   [Full Text] [Related]  

  • 49. [Institutional cost reimbursement by medical director's past contracts according to the health structure regulation of 1993].
    Rieger HJ
    Dtsch Med Wochenschr; 1993 Mar; 118(11):395-7. PubMed ID: 8453911
    [No Abstract]   [Full Text] [Related]  

  • 50. The unordered test: cost of the benefit vs. benefit of the cost.
    Winkelman JW; Bernstein LH
    Pathologist; 1985 Jul; 39(7):12-6. PubMed ID: 10317618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hierarchical information system for the cost analysis of clinical laboratory tests.
    Hause LL; Sasse EA; Perry BW
    J Med Syst; 1985 Jun; 9(3):139-44. PubMed ID: 3840518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is that new instrument a winner?
    Stafford AC
    MLO Med Lab Obs; 1986 Apr; 18(4):24-8. PubMed ID: 10317714
    [No Abstract]   [Full Text] [Related]  

  • 53. Exclusive contracts: do they constrain competition?
    McGraner RC
    Radiol Manage; 1988; 10(1):28-32. PubMed ID: 10302263
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CAP v. Heckler and HCFA's modification of TEFRA regulations.
    Bierig JR; Dechene JC
    Pathologist; 1984 Oct; 38(10):661-3. PubMed ID: 10273583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effective determination of patient charges.
    Pfeil DP
    Hosp Mater Manage Q; 1979 Nov; 1(2):27-38. PubMed ID: 10244252
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful physician affiliations through fair compensation.
    Loudermilk RC
    Healthc Financ Manage; 1995 Mar; 49(3):54-5, 57. PubMed ID: 10146152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COBRA coils for strike against clinical lab fees.
    MLO Med Lab Obs; 1986 Jun; 18(6):25-6. PubMed ID: 10300963
    [No Abstract]   [Full Text] [Related]  

  • 58. Instituting change to cut lab costs.
    Pelton TN
    Pathologist; 1985 Jul; 39(7):17-20. PubMed ID: 10272022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Those hospital specialties: alive and very healthy.
    Holoweiko M
    Med Econ; 1983 Mar; 60(5):148-53, 157, 160 passim. PubMed ID: 10258808
    [No Abstract]   [Full Text] [Related]  

  • 60. Join hospitals in working toward a common reimbursement goal.
    Scibetta LP
    Pathologist; 1983 Aug; 37(8):552-5. PubMed ID: 10273423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.